New Scaffolds of Proteasome Inhibitors: Boosting Anticancer Potential by Exploiting the Synergy of In Silico and In Vitro Methodologies

New Scaffolds of Proteasome Inhibitors: Boosting Anticancer Potential by Exploiting the Synergy of In Silico and In Vitro Methodologies

Cancer is a complex multifactorial disease whose pathophysiology involves multiple metabolic pathways, including the ubiquitin–proteasome system, for which several proteasome inhibitors have already been approved for clinical use. However, the resistance to existing therapies and the occurrence of s...

Full description

Bibliographic Details
Main Authors: Romina A. Guedes, Jorge H. Grilo, Andreia N. Carvalho, Pedro M. P. Fernandes, Ana S. Ressurreição, Vanessa Brito, Adriana O. Santos, Samuel Silvestre, Eleonora Gallerani, Maria João Gama, Riccardo Gavioli, Jorge A. R. Salvador, Rita C. Guedes
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Pharmaceuticals
Subjects:
ubiquitin–proteasome system
proteasome
proteasome inhibitors
cancer
leukemia
lymphoma
Online Access:https://www.mdpi.com/1424-8247/16/8/1096

Internet

https://www.mdpi.com/1424-8247/16/8/1096

Similar Items